The prevalence of diabetes in Burundi has been increasing steadily over the years, with an estimated 3.5% of the population affected by the disease. As a result, the demand for anti-diabetes drugs has been on the rise in the country.
Customer preferences: Burundian consumers tend to prefer generic drugs over branded ones due to their affordability. This is because the majority of the population lives below the poverty line, and many cannot afford expensive medication. As a result, generic drugs account for a significant portion of the anti-diabetes drugs market in Burundi.
Trends in the market: The Burundian government has been taking steps to improve access to healthcare in the country, which has had a positive impact on the anti-diabetes drugs market. For example, the government has been investing in healthcare infrastructure and increasing the number of healthcare workers in the country. This has led to increased awareness of diabetes and its treatment, which has in turn driven demand for anti-diabetes drugs.
Local special circumstances: One of the unique challenges facing the anti-diabetes drugs market in Burundi is the lack of reliable electricity. This makes it difficult for healthcare facilities to store and distribute medication, particularly those that require refrigeration. As a result, some drugs may be less effective due to improper storage, which can be a concern for patients.
Underlying macroeconomic factors: Burundi is one of the poorest countries in the world, with a GDP per capita of just $261. This means that many Burundians cannot afford expensive medication, which has driven demand for generic drugs. In addition, the country has a high burden of communicable diseases, which has led to a relatively low level of investment in non-communicable disease treatments such as anti-diabetes drugs. However, the government has recognized the importance of addressing non-communicable diseases such as diabetes and has taken steps to improve access to treatment.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
